SOURCE: Easton Pharmaceuticals, Inc.

November 04, 2013 08:30 ET

Easton Pharmaceuticals Is Provided a Manufacturing, Regulatory Filing Update and Forward Sales Estimates for VIORRA

TORONTO, ON--(Marketwired - Nov 4, 2013) - Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products announced today an update to its recently announced regulatory filing in Mexico for its Viorra product through BMV Medica S.A. de C.V. (BMV), a Mexican Regulatory & Licensing consultancy in Mexico, Latin America and South-East Asia.

As previously announced, BMV Medica S.A. de C.V. has estimated the regulatory submission in Mexico will require six to seven months until an anticipated marketing approval is obtained. According to BMV, discussions on Easton's behalf have been initiated to source a distribution partner within Mexico. In addition, BMV has advised Easton they have also sourced out a product specific US FDA-approved manufacturing partner and facility within Mexico which they believe could be more cost effective and better suited to manufacture Viorra and other products. Although Easton has previously sourced out a manufacturing company for Viorra and any of its other products including other products presently under discussion, BMV believes its Mexico manufacturer is better suited for the Company's needs as well as providing a boost to its regulatory filing with the Mexican government. It is anticipated that Easton will be making a decision on its manufacturing partner within the next 30 days which will be required for the regulatory submission.

BMV has provided what it believes to be realistic projections towards possible sales figures that could be attained once an approval has been granted by regulatory authorities in Mexico. BMV believes an approval in Mexico would allow for instantaneous approvals and acceptance by governments in other parts of Latin America which opens up another huge potential market for VIORRA. According to BMV, Sales targets could reach between $10 to $14 million USD within 24 months of launch. These projections are based around other previously approved products, the size of the market, and the belief that a VIORRA type product would be eagerly accepted by women in these markets with a proper distribution partner. As conveyed by BMV, they have entered into discussions on Easton's behalf with several targeted distribution companies focused on sales and marketing in the women's health, sexual arousal disorder and the sexual wellness market.

Ms. Mendoza Vazquez of BMV, stated: "Once we finalize the discussions to secure a local high-quality manufacturing facility here in Mexico, the timelines towards regulatory approval can be shortened. As in other industries, Mexico has a highly skilled work force, with advantageous cost structures for pharmaceutical manufacturing. In addition, if properly marketed we believe Viorra could be the market leader in this segment, and very quickly attain the sales levels of similar products marketed for men, which we have seen to be in the tens of millions of dollars annually."

About BMV Medica, S.A. de C.V.:

BMV was founded in 2009, by a group of pharmaceutical professionals, whose background includes regulatory approvals in Mexico for several classes of Health Sector Products, including Medical Devices, Medicines, and a combination of Drug/Device products, as well as nutraceuticals, and cosmetic products. In addition, BMV works with North American and European pharmaceutical companies to assist them with local regulatory approvals and distribution agreements. Ms. Mendoza Vazquez, President of BMV, has previously worked in Marketing, Regulatory and Sales for Schering Plough Mexico, and other Pharmaceutical companies.

About Easton Pharmaceuticals Inc

Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered Drugs and therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The world market for these conditions is in excess of $10 billion.

The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.

For More Information Visit http://www.eastonpharma.com & http://www.ashleybiomedical.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," "should," expect," "anticipate," "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.